达比加群酯联合PCI治疗房颤伴冠心病的临床观察

Clinical Observation of Dabigatran Axetil Combined with PCI in the Treatment of Atrial Fibrillation with Coronary Heart Disease

目的探讨达比加群酯联合经皮冠状动脉介入(PCI)术治疗房颤伴冠心病的临床效果。方法回顾性分析2019年1月—2019年12月接受治疗的85例房颤伴冠心病患者研究资料,将采用PCI术+华法林抗凝治疗的40例患者纳入对照组,将采用PCI术+达比加群酯抗凝治疗的45例患者纳入观察组。观察两组治疗前及治疗6个月后实验室指标,并对比两组不良事件发生率。结果治疗6个月后,两组血小板计数(PLT)、C反应蛋白(CRP)、D-二聚体(D-D)、纤维蛋白原(FIB)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组不良事件发生率(8.89%)与对照组(15.00%)比较,差异无统计学意义(P>0.05)。结论达比加群酯联合PCI术治疗房颤伴冠心病可获得良好抗凝效果,且不会增加不良事件发生率。

Objective To investigate the clinical effect of dabigatran axetil combined with percutaneous coronary intervention(PCI)in the treatment of atrial fibrillation with coronary heart disease.Methods The data of 85 patients with atrial fibrillation and coronary heart disease who were treated in General Hospital of Jinshui District from January 2019 to December 2019 were retrospectively analyzed.40 patients who were treated with PCI and warfarin anticoagulant therapy were included in the control group,and 45 patients who were treated with PCI and dabigatran dipivoxil anticoagulation therapy were included in the observation group.The laboratory indexes before and after 6 months of treatment were observed,and the incidence of adverse events was compared between the two groups.Results After 6 months of treatment,the levels of platelet(PLT),C-reactive protein(CRP),D-Dimer(D-D)and fibrinogen(FIB)in the two groups were lower than those before treatment,and the observation group was lower than the control group(P<0.05);the incidence of adverse events in the observation group(8.89%)was not significantly different from that in the control group(15.00%)(P>0.05).Conclusion Dabigatran dipivoxil combined with PCI in the treatment of atrial fibrillation with coronary heart disease can obtain good anticoagulant effect without increasing the incidence of adverse events.